BioCentury | Mar 19, 2020
Product Development

DARPA’s gambles might have created the best hopes for stopping COVID-19

...this platform would receive pre-approval we could anticipate a situation where once the RNA or DNA technology...
BioCentury | Sep 13, 2019
Tools & Techniques

Enzymes aim to beat chemistry by creating longer, speedier, cleaner DNA strands

The first new chemistry for DNA writing in 30 years is gathering steam, with enzymatic synthesis startups developing platforms to generate longer, purer DNA strands in record time. While the new players aim to outperform...
BioCentury | Jun 13, 2019
Product Development

Why BioMarin took gene therapy manufacturing into its own hands

...one at the time. “We didn’t have vector scientists. We were mostly working on recombinant DNA technology...
BioCentury | Mar 19, 2019
Regulation

Talk less, do more: Germline gene editing needs real plans, not just moratoria

...a driver of the Asilomar conference that laid the groundwork for responsible use of recombinant DNA technology...
BioCentury | Mar 13, 2019
Politics & Policy

Researchers call for global moratorium, not outright ban, on germline editing

...Berg, a driver of the Asilomar conference that set guidelines for responsible use of recombinant DNA technology...
BioCentury | Dec 7, 2018
Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
BioCentury | Nov 28, 2018
Clinical News

Critics continue to pile on as CRISPR researcher describes informed consent, review process

...a Meeting" ). Baltimore was a key organizer of the 1975 Asilomar meeting on recombinant DNA technology...
BioCentury | Oct 19, 2018
Politics, Policy & Law

CFIUS waiting game

Biotech and its investors must wait to find out how much of the industry will be caught up in the CFIUS dragnet of foreign investment in American companies, but the U.S. Treasury has given itself...
BioCentury | Nov 17, 2016
Translation in Brief

Point taken

...mechanism that may explain the unexpected potency and pinpoint specificity of its third-generation antisense (3GA) DNA technology...
BioCentury | Jun 2, 2016
Product R&D

Local reagent makes good

Genisphere LLC is converting its 19 year-old diagnostic reagents into new-age delivery vehicles. The company is repurposing its 3DNA assay technology into nanoparticles that it believes can bring high-valency cargo to target tissues without getting...
Items per page:
1 - 10 of 150
BioCentury | Mar 19, 2020
Product Development

DARPA’s gambles might have created the best hopes for stopping COVID-19

...this platform would receive pre-approval we could anticipate a situation where once the RNA or DNA technology...
BioCentury | Sep 13, 2019
Tools & Techniques

Enzymes aim to beat chemistry by creating longer, speedier, cleaner DNA strands

The first new chemistry for DNA writing in 30 years is gathering steam, with enzymatic synthesis startups developing platforms to generate longer, purer DNA strands in record time. While the new players aim to outperform...
BioCentury | Jun 13, 2019
Product Development

Why BioMarin took gene therapy manufacturing into its own hands

...one at the time. “We didn’t have vector scientists. We were mostly working on recombinant DNA technology...
BioCentury | Mar 19, 2019
Regulation

Talk less, do more: Germline gene editing needs real plans, not just moratoria

...a driver of the Asilomar conference that laid the groundwork for responsible use of recombinant DNA technology...
BioCentury | Mar 13, 2019
Politics & Policy

Researchers call for global moratorium, not outright ban, on germline editing

...Berg, a driver of the Asilomar conference that set guidelines for responsible use of recombinant DNA technology...
BioCentury | Dec 7, 2018
Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
BioCentury | Nov 28, 2018
Clinical News

Critics continue to pile on as CRISPR researcher describes informed consent, review process

...a Meeting" ). Baltimore was a key organizer of the 1975 Asilomar meeting on recombinant DNA technology...
BioCentury | Oct 19, 2018
Politics, Policy & Law

CFIUS waiting game

Biotech and its investors must wait to find out how much of the industry will be caught up in the CFIUS dragnet of foreign investment in American companies, but the U.S. Treasury has given itself...
BioCentury | Nov 17, 2016
Translation in Brief

Point taken

...mechanism that may explain the unexpected potency and pinpoint specificity of its third-generation antisense (3GA) DNA technology...
BioCentury | Jun 2, 2016
Product R&D

Local reagent makes good

Genisphere LLC is converting its 19 year-old diagnostic reagents into new-age delivery vehicles. The company is repurposing its 3DNA assay technology into nanoparticles that it believes can bring high-valency cargo to target tissues without getting...
Items per page:
1 - 10 of 150